AR Solutions In Action

CDC's Investments to Combat Antibiotic Resistance Threats

FISCAL YEAR 2021

NEW MEXICO \$1,724,108

Funding for AR Activities
Fiscal Year 2021

One of 10 sites for the Emerging Infections Program

FUNDING TO STATE HEALTH DEPARTMENTS



\$710,588

RAPID DETECTION & RESPONSE: State, territory, and local public health partners fight AR in healthcare, the community, and food.

Programs use the AR Lab Network to rapidly detect threats and then implement prevention, response, and antibiotic stewardship to stop the spread of resistant germs. Additional resources, appropriated to CDC to fight COVID-19, will also help in the fight against AR by improving infection prevention and control in healthcare facilities.



FOOD SAFETY projects protect communities by rapidly identifying drug-resistant foodborne bacteria to stop and solve outbreaks and improve prevention.

\$123,165

New Mexico uses whole genome sequencing to track and monitor local outbreaks of *Listeria*, *Salmonella*, *Campylobacter*, and *Escherichia coli* and uploads sequence data into PulseNet for nationwide monitoring of outbreaks and trends. In Fiscal Year 2021, New Mexico continued monitoring these isolates for resistance genes. When outbreaks are detected, local CDC-supported epidemiologists investigate the cases to stop spread.



\$97,980

FUNGAL DISEASE projects improve our ability to track antifungal resistance and stop it from spreading.

With funding for fungal disease surveillance, New Mexico increased their ability to identify fungal diseases, monitor for new and emerging resistance, and implement strategies to prevent its spread in high-risk areas. Improving detection for fungal diseases, like *Candida auris*, means patients receive appropriate treatment and while reducing unnecessary antibiotic use.



\$13.000

GONORRHEA RAPID DETECTION & RESPONSE works with state and local epidemiology and laboratory partners to test for and quickly respond to resistant gonorrhea to stop its spread in high-risk communities. Only one treatment option remains for gonorrhea and resistance continues to grow.

The Gonococcal Isolate Surveillance Project (GISP) informs national treatment guidelines and monitors how well antibiotics work on laboratory samples collected from sentinel sexually transmitted disease (STD) clinics, which often are the first to detect the threat. Select STD clinics also enhance surveillance by collecting additional gonococcal isolates from women and from extragenital sites.

of 2 This data represents CDC's largest funding categories for AR. It shows extramural funding that supports AR activities from multiple funding lines

AR: antibiotic resistance HAI: healthcare-associated infection

CDC provides critical support in the U.S. and abroad to protect people from antibiotic resistance.



AR Solutions In Action

CDC's Investments to Combat Antibiotic Resistance Threats

FISCAL YEAR 2021

NEW MEXICO AR Investments (cont.)



EMERGING INFECTIONS PROGRAM (EIP) sites improve public health by translating population-based surveillance and research activities into informed policy and public health practice. This work is also funded in part by resources appropriated to CDC to support its response to coronavirus disease 2019 (COVID-19).

\$779,375

The New Mexico EIP performs population-based surveillance for candidemia, Clostridium difficile, and resistant Gram-negative bacteria; develops and standardizes surveillance and outbreak response for foodborne infections; and conducts HAI and antibiotic use prevalence surveys. Learn more: www.cdc.gov/hai/eip.

COVID-19: coronavirus dis

